1 October 2015 - CADTH has received notice of a pending resubmission from BioMarin for elosulfase alfa (Vimizim) for patients with Mucopolysaccharidosis IVA (Morquio A syndrome).  For information about the patient input process or for additional instructions, please see the patient input page of the CADTH website.

For more details, go to: https://www.cadth.ca/elosulfase-alfa-vimizim